๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Hamlet BioPharma AB (publ) (XSAT:HAMLET.B)
Sweden flag Sweden ยท Delayed Price ยท Currency is SEK
6.08
+0.10 (1.67%)
At close: Sep 30, 2026

Hamlet BioPharma AB Company Description

Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer and infections in Sweden.

The company is developing Alpha1H for the treatment of bladder cancer; and IL-1 receptor antagonist (anakinra) for the treatment of bladder pain syndrome and recurrent acute cystitis that are in Phase II clinical trials, as well as Alpha1H for the treatment of brain tumor; Hamlet for the treatment of colon and rectal cancer and oral cancer; RNA Pol II inhibitor โ€“ protein for preventive anti-inflammatory and antibacterial effects; RNA Pol II inhibitor โ€“ bacteria for prevention of inflammation and treatment of infection; IRF7 inhibitor, siRNA for prevention of inhibits severe bacterial infections; and Anti-TBC peptide for prevention of pulmonary tuberculosis that are in preclinical stage.

It has a collaboration agreement with University of Iowa for development of Alpha1H for patients with severe bladder cancer.

Hamlet BioPharma AB (publ) was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023.

The company was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) operates as a subsidiary of Linnane Pharma AB.

Hamlet BioPharma AB (publ)
CountrySweden
Founded1999
IndustryBiological Products, Except Diagnostic Substances
Employees6
CEOCatharina Svanborg

Contact Details

Address:
BMC D10
Lund, 222 42
Sweden
Phone46 40 12 25 00
Websitehamletbiopharma.com

Stock Details

Ticker SymbolHAMLET.B
ExchangeSpotlight Stock Market
Fiscal YearJuly - June
Reporting CurrencySEK
ISIN NumberSE0015661152
SIC Code2836

Key Executives

NamePosition
Catharina SvanborgChief Executive Officer
Jakob TestadChief Financial Officer